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Abstract
Background: Depot antipsychotics are a treatment option for medication nonadherence in patients with
schizophrenia. Nonadherence can lead to increased relapse and hospitalization rates. This article reports
hospitalization data before and after initiation of olanzapine long-acting injection (LAI), a depot antipsychotic.
Methods: Data were assessed from an ongoing, multinational, prospective, observational post-authorisation safety
study being conducted to evaluate post-injection delirium/sedation syndrome (PDSS), an adverse reaction that can
occur following injection of olanzapine LAI. Eligible patients were aged ≥18 years, diagnosed with schizophrenia,
were prescribed olanzapine LAI, and lived outside the United States. Psychiatric hospitalization and medication data
were collected retrospectively for the 6-month period before study entry and prospectively throughout the study.
Paired t-tests and McNemar’s tests were used to assess changes in hospitalization incidence and duration. Stepwise
Cox proportional hazards models assessed factors associated with hospitalizations. Analyses were based on data
from the first 3 years of the continuously enrolling study (N = 668).
Results: The average duration of olanzapine LAI exposure for all patients was 0.768 years. Of the 529 patients
who received at least 1 injection of olanzapine LAI and were not hospitalized at study entry, 8.1 % had at least
1 subsequent psychiatric hospitalization with a mean duration of 2.0 days. Of the 288 patients who had a >6-
month follow-up, 8.3 % had at least 1 post-baseline psychiatric hospitalization with a mean duration of 2.3 days.
The incidence of hospitalizations in the 6-month period after treatment was significantly lower than that in the
6-month period prior to treatment (8.3 vs 32.6 %, respectively; P < 0.001). Furthermore, mean hospitalization
duration decreased from 11.5 days in the 6-month period before treatment to 2.3 days in the 6-month period
after treatment (P < 0.001). Psychiatric hospitalization in the prior 12 months (P < 0.0001) and recreational drug
use within 24 h of baseline visit (P = 0.015) were identified as potential predictors of time to first psychiatric
hospitalization after beginning to take olanzapine LAI. At the time of interim analysis, 5 PDSS events had
occurred, which was too few for a full analysis of those events.
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Conclusions: Results indicate a significant reduction in the incidence and days of hospitalization from the
6-month period before to the 6-month period after olanzapine LAI initiation, which suggests reduced relapse
and hospitalization during treatment. Results should be interpreted with caution due to the observational nature
of the study and use of retrospective baseline data.
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Background
Schizophrenia is a chronic disease that affects almost 1 %
of the world’s population [1]. Nonadherence or partial ad-
herence to drug treatment is relatively common in many
chronic illnesses, including schizophrenia [2–6], and the
average rate of nonadherence to antipsychotics is approxi-
mately 50 % [7]. Medication nonadherence contributes to
symptom exacerbation, hospitalization, and relapse [8].
Seventy-five percent of patients who discontinue their
medication experience significant exacerbation of symp-
toms over 1 year compared with 25 % of those who adhere
to their medication [9, 10].
Costs associated with treatment received following
relapse may comprise the largest segment of treatment
costs related to schizophrenia [11–14]. A review of
studies addressing the economic impact of anti-
psychotic nonadherence in individuals with schizophre-
nia revealed that poor adherence to antipsychotic
medications was consistently associated with a higher
risk of relapse and rehospitalization, as well as with
higher hospitalization costs [15]. Moreover, it has been
estimated that most of the direct costs of schizophrenia
result from hospitalization or other residential care [15,
16]. Thus, treatments associated with increased adher-
ence and reduced hospitalizations are important for the
clinical management of schizophrenia.
Long-acting injectable antipsychotic medications are
an important option to help minimize nonadherence be-
cause they allow for non-adherent patients to be identi-
fied sooner and they remove the need for patients to
take medication every day, increasing treatment adher-
ence [17, 18]. Olanzapine long-acting injection (LAI) is a
sustained-release intramuscular dosage formulation con-
sisting of a pamoate salt of olanzapine. Olanzapine LAI
has been shown to be efficacious for the treatment of
schizophrenia in both actively psychotic [19] and stable
patients [20]. Using a large claims database, Peng et al.
[21] found that psychiatric hospitalizations of patients
with schizophrenia who were treated with LAIs de-
creased from 49.7 % during the 6 months before LAIs
initiation to 22.4 % in the 6 months after LAIs initiation.
To assess the impact of olanzapine LAI use on
hospitalization, we evaluated the hospitalization rates
and durations in the 6 months before and the 6 months
after study entry in patients participating in an ongoing
multinational observational study. The study was designed
with the primary objective of collecting prospective data
on post-injection delirium/sedation syndrome (PDSS), an
adverse event that has been reported during treatment
with this formulation [22, 23]. However, data on patient
medication use and hospitalization, historically as well as
prospectively, were also collected, providing a unique
opportunity to assess the potential impact of olanzapine
LAI on outcome measures closely tied to medication
adherence. Exploratory analyses were also conducted to
assess whether any patient baseline characteristics might
be associated with subsequent risk of hospitalization.
Methods
Study design
Data were collected as part of a non-interventional, pro-
spective observational post-authorization safety study
(PASS) designed to assess the incidence of PDSS events in
patients with schizophrenia being treated commercially
with olanzapine LAI (see Additional file 1 for STROBE
checklist of observational studies) . This report is an in-
terim analysis of the data collected between April 2009
(first patient enrolled) and March 2012 (the first planned
interim data cutoff for the study for the purpose of evalu-
ating hospitalization data). This study is ongoing. As of
that data cutoff, the study was being conducted in mul-
tiple sites in Australia, Austria, Belgium, Czech Republic,
Denmark, Finland, France, Germany, Greece, Hungary,
Ireland, Italy, Romania, Slovakia, Spain, Sweden, and the
United Kingdom.
The study was approved in all countries at the site, re-
gional, or national level, depending on the country and
local regulations. Patient also consent followed country-
specific regulations. The study protocol was approved by
the Ethical Review Board at each study center. Please see
Additional file 2 for a full list of participating centers
and names of ethics boards.
All patients were receiving commercially available
olanzapine LAI in accordance with their physicians’
standard of care. Treatment for schizophrenia with
olanzapine LAI was prescribed at the discretion of the
investigator and was not provided for or reimbursed by
the study sponsor. Throughout the study, effort was
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made to avoid interference with clinical practice to
maintain real-life settings. Investigators were instructed
to make treatment decisions independent of the study
and then determine whether patients were eligible for
study inclusion on the basis of the entry criteria.
Patients
Eligible patients were men and women aged ≥18 years
who had a diagnosis of schizophrenia and whose physi-
cians had prescribed olanzapine LAI. Patients could be
enrolled in the study regardless of whether they began
treatment with olanzapine LAI prior to the start of the
study. Study inclusion was also predicated on the will-
ingness of the patient to sign an informed consent form
to release medical information. Patients could not par-
ticipate if they were investigator site personnel directly
affiliated with the study or a member of their immediate
families, employees of Eli Lilly and Company, or unwill-
ing to provide written consent to release medical infor-
mation or other required forms to participate in the
study. Patients were not paid for their participation in
the study.
Data collection
Data collection for the study occurred during routine
visits within the normal course of healthcare. Baseline
data collection occurred at the first administration of
olanzapine LAI after patient consent. Data collected at
baseline included demographics, year of initial schizo-
phrenia diagnosis, previous antipsychotic medication
use, history of alcohol and recreational drug use, and
previous psychiatric hospitalization information. Data
were also collected at any subsequent office visits during
which the patient received an injection of olanzapine
LAI. The frequency of injection visits was at the discre-
tion of the investigator. Data collected at every injection
visit included adverse events, concomitant medications,
and psychiatric hospitalization information.
Statistical methods
Analyses were applied to all patients who received
olanzapine LAI unless otherwise specified. Descriptive
statistics were used to describe the study population. For
analyses of changes in post-baseline incidence and the
duration of psychiatric hospitalization, patients who had
exposure to olanzapine LAI in the 6-month period prior
to baseline were excluded. McNemar’s test of change
was used to compare the proportion of previous psychi-
atric hospitalizations and the proportion of post-baseline
psychiatric hospitalizations among patients with at least
1 injection and without any baseline hospitalizations
(defined as patients who were not hospitalized when
they initiated treatment with olanzapine LAI). A paired
Student’s t-test was performed for change in days of
hospitalization from previous to post-baseline among
patients with at least 1 injection and without baseline
hospitalization. Because not all patients currently en-
rolled in the study had the opportunity for at least
6 months of follow-up, these pre vs. post analyses were
performed both to include all of the data and to restrict
data to only the population of patients who had the op-
portunity for 6 months of follow-up (compared to their
6 months prior to baseline). This may result in slightly
conservative analyses because the average exposure time
in the follow-up period was greater than the 6-month
baseline period.
Stepwise (forward) Cox regression was used to identify
baseline risk factors associated with time to first psychi-
atric hospitalization among patients not hospitalized
when they initiated olanzapine LAI treatment. Data are
presented as hazard ratios (HRs) and 95 % confidence
intervals (CIs). The following variables were input as po-
tential variables to be included in the stepwise Cox re-
gression model building process: continuous variables,
including age, age at time of first schizophrenia episode,
years since first schizophrenic episode, weight, and body
mass index; and categorical variables, including gender
(male/female), race (white/non-white), recreational drug
use within 24 h of receiving first injection of olanzapine
LAI (yes/no), alcohol use within 24 h of receiving first
injection of olanzapine LAI (yes/no), country (Australia,
Austria, Belgium, Czech Republic, Denmark, Finland,
France, Germany, Greece, Hungary, Ireland, Italy,
Romania, Slovakia, Spain, Sweden, or United Kingdom),
antipsychotic treatment during the previous 2 years (yes/
no), concomitant antipsychotics (yes/no), other psychiatric
medications (yes/no), and psychiatric hospitalization in
prior 6 and 12 months (yes/no). The final model in-
cluded only statistically significant covariates (i.e., those
with P < 0.10 based on the Wald chi-square test).
Results
Baseline patient demographics and clinical characteristics
As of March 31, 2012, at total of 10,085 injections of
olanzapine LAI were given to 668 patients in the study.
Table 1 shows the demographic and clinical characteris-
tics of the patients at baseline. Patients were mostly male
(61.8 %), had a mean age of 40.8 years, had a mean
weight of approximately 79.4 kg, and were mostly white
(93.3 %). Mean age at onset of schizophrenia was
29.2 years.
Disposition, dosing, and concomitant medication
The average (standard deviation [SD]) duration of olan-
zapine LAI exposure for all patients was 0.768 (0.69)
years, which reflects the ongoing enrollment in the study
at the time of the interim analysis. During this time,
31.7 % of patients discontinued the study. The most
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frequent dose of olanzapine LAI was 300 mg every
2 weeks, which was used for 47.6 % of all injections.
Hospitalizations
A total of 83 patients already had exposure to olanzapine
LAI in the 6 months prior to study entry, leaving 585
patients eligible for post-baseline hospitalization ana-
lyses. At baseline, 248 (42.4 %) of 585 patients reported
a psychiatric hospitalization in the 6-month period prior
to study enrollment, with 273 (46.7 %) patients experien-
cing a psychiatric hospitalization in the 12-month period
prior to enrollment. A total of 56 (10.7 %) patients were
still hospitalized at the time of olanzapine LAI initiation
and study entry. Across all patients, the mean duration
of the psychiatric hospitalization reported was 21.7 days
in the 6-month period prior to study enrollment and
33.1 days in the 12-month period prior to enrollment.
Among only those patients hospitalized, the mean dur-
ation of hospitalization was 51.2 days in the 6 months
before study enrollment and 71.0 days in the 12 months
before study enrollment. Table 2 summarizes the rate
and duration of post-baseline psychiatric hospitalizations
at initiation of olanzapine LAI treatment. Of the 529 pa-
tients who were not hospitalized at study entry and re-
ceived at least 1 injection of olanzapine LAI, 43 (8.1 %)
had at least 1 subsequent psychiatric hospitalization,
with a mean duration of 2.0 days. Of the 288 patients
who had >6-months follow-up, 24 (8.3 %) had at least 1
post-baseline psychiatric hospitalization with a mean
duration of 2.3 days.
Table 3 demonstrates that the incidence of hospitali-
zations after olanzapine LAI treatment was statistically
significantly lower than the incidence of hospitaliza-
tions in the 6-month period prior to olanzapine LAI
treatment (P < 0.001). In addition, there was a signifi-
cant reduction in the number of days hospitalized;
mean hospitalization duration was 11.5 days in the
Table 1 Baseline patient demographics and clinical
characteristics of patients receiving olanzapine long-acting
injection
Characteristic All Patients with ≥1
Injection (N = 668)









Weight (kg), mean (SD) 79.4 (17.2)a
Age at first episode of schizophrenia (years),
mean (SD)
29.2 (10.0)
Psychiatric hospitalization, prior 12 months
Yes, n (%) 321 (48.1)
Number of days (mean, SD) 39.1 (81.6)
Number of days – among only patients with
a hospitalization (mean, SD)
81.4 (102.2)
Psychiatric hospitalization, prior 6 months
Yes, n (%) 289 (43.3)
Number of days (mean, SD) 24.3 (46.1)
Number of days – among only patients with
a hospitalization (mean, SD)
56.2 (56.0)
Antipsychotic treatment previous 2 years
Yes, n (%) 590 (88.3)
Abbreviations: N/n number of patients, SD standard deviation
aFive patients were missing from the analysis
Table 2 Rate and duration of post-baseline psychiatric hospitalizationsa




No N 529 288
Patients with ≥1 post-baseline hospitalization, n (%) 43 (8.1) 24 (8.3)
Days of hospitalization, mean (SD) 2.0 (12.0) 2.3 (14.3)
Days of hospitalizations among patients with a
hospitalization, mean (SD)
24.9 (35.0) 27.0 (43.1)
Yes N 56 29
Patients with ≥1 post-baseline hospitalization, n (%) 6 (10.7) 5 (17.2)
Days of hospitalization, mean (SD) 3.6 (20.5) 6.8 (28.3)
Days of hospitalizations among patients with a
hospitalization, mean (SD)
33.3 (58.5) 39.4 (63.3)
Abbreviations: LAI long-acting injection, N/n number of patients, SD standard deviation
aAnalysis included only patients who started treatment with olanzapine LAI at time of study entry
bDefined as hospitalization upon initiation of olanzapine LAI treatment
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prior 6 months and decreased to 2.3 days in the post-
baseline period (P < 0.001). These pre vs. post analyses
included only those patients with opportunity for at
least 6-months follow-up. Analyses using data from all
patients were consistent in demonstrating significant
reductions in the incidence of hospitalization and the
number of days hospitalized.
Figure 1 shows the Kaplan-Meier curve of time to
hospitalization in the 36 months after the initiation of
olanzapine LAI treatment. Hospitalization rates were low
over the course of treatment, with approximately 80 % of
patients remaining unhospitalized after 36 months.
Table 4 summarizes the risk factors associated with
time to first psychiatric hospitalization that were identi-
fied using a stepwise Cox regression approach. Among
all of the variables used in the model, the strongest asso-
ciation identified was that patients who were hospital-
ized in the previous 12 months for psychiatric reasons
were more likely to be hospitalized during the study
(HR = 5.00, P < 0.0001). Recreational drug use within
24 h of the baseline study visit (HR = 5.90, P = 0.015)
was also identified as a potential risk factor associated
with time to first psychiatric hospitalization, although
the small sample size and large CI limits are noted.
Post-injection delirium/sedation syndrome
Five patients experienced 5 adverse events that were de-
termined to be PDSS events. As of March 31, 2012, based
on 10,085 injections of olanzapine LAI given to 668 pa-
tients, PDSS events occurred in approximately 0.05 % of
injections, or 0.75 % of patients. Due to the small number
of PDSS events, analyses on PDSS risk factors could not
be conducted as part of this interim analysis and will be
conducted on final data lock (after achieving the protocol-
specified target of 92,500 injections).
Discussion
Although the primary purpose of this ongoing observa-
tional study is to conduct a post-marketing evaluation
of PDSS in patients with schizophrenia treated with
olanzapine LAI, interim data analysis after the first
3 years of data collection allowed for the examination
of patient baseline characteristics and rates of psychi-
atric hospitalization before and after initiation of olan-
zapine LAI. Psychiatric hospitalization is an important
clinical outcome that carries a high personal and eco-
nomic burden. It can also serve as an indicator of patient
nonadherence and is relevant when evaluating a depot
medication that is meant to address nonadherence. In-
terim analysis of the current study found that patients re-
ceiving >6 months of olanzapine LAI in the post-baseline
period had significantly lower rates of psychiatric
hospitalization than during the 6 months before study
baseline (incidence: 8.3 % versus 32.6 %, respectively;
P < 0.001), as well as reduced hospitalized days (mean
[SD] days: 11.5 [23.8] versus 2.3 [14.3]; P < 0.001). Patients
with exposure to olanzapine LAI in the 6 months prior to
Table 3 McNemar’s test of pre- versus post-baseline
hospitalizationsa
Post-baseline Hospitalization
Previous Hospitalizationb No Yes P-value
No, n (%) 183 (63.5) 11 (3.8) <0.001
Yes, n (%) 81 (28.1) 13 (4.5)
Abbreviation: LAI long-acting injection, SD standard deviation
aAnalysis included only patients who started treatment with at least 1
injection of olanzapine LAI at time of study entry, without baseline
hospitalization, and who had opportunity for at least 6 months of follow-up
bAnalysis included hospitalization in the 6 months prior to initiating
olanzapine LAI treatment
Patients at risk    585          369          285         226          163          111          72            47           27  12             8             6
Time to First Hospitalization (months)



































Fig. 1 Time to first hospitalization for patients treated with olanzapine long-acting injection at study entry. Hospitalization rates were low over
the course of treatment, with an estimate of about 80 % of patients remaining unhospitalized after 36 months
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study entry were excluded from the hospitalization ana-
lyses to reduce any potential effect of prior exposure of
olanzapine LAI on the outcome of hospitalization.
The results related to hospitalization data in this study
are consistent with those reported previously in literature.
In a recent study in previously nonadherent patients,
those receiving depot typical antipsychotics versus oral
typical antipsychotics reported better medication continu-
ation, decreased hospitalization rates, and decreased mean
number of hospitalizations [24]. Similarly, a study in a
home health care setting in Taiwan showed a significantly
lower risk for psychiatric rehospitalization in patients re-
ceiving LAI antipsychotics than those treated with oral
medication [25]. In addition, a United States Medicaid
database study reported that use of LAI medications is as-
sociated with a longer time to the first hospitalization for
any cause and for schizophrenia; moreover, the authors
also reported that a longer use duration of LAI antipsy-
chotics (at least 6 months relative to those treated for
shorter durations) is associated with a decreased num-
ber of hospitalizations, decreased hospital length of
stay, and reduced hospital payment—thus using fewer
hospital resources [26]. Findings from randomized clin-
ical trials of olanzapine LAI have also produced similar re-
sults indicating favorable changes in hospitalization [27].
Across all patients in the current study, Kaplan-Meier
estimate indicated that approximately 80 % of patients
remained free of psychiatric hospitalization during the
3-year data collection period. Time to first psychiatric
hospitalization was best predicted by psychiatric
hospitalization in the 12 months prior to starting olan-
zapine LAI. This finding is consistent with previous re-
search that has shown past hospitalizations to be a
strong predictor of future hospitalizations [27–30]. In
addition, recreational drug use within 24 h of receiving
the first injection of olanzapine LAI was identified as a
potential baseline correlate of time to first psychiatric
hospitalization. However, caution should be taken when
interpreting the individual contributions of each factor
due to the small subgroup size and the potential correl-
ation among the variables in the final model.
At the time of the interim analysis, 5 PDSS events had
occurred in 5 patients in the trial, indicating an
incidence of 0.05 % of injections, or approximately 1
event per 2017 injections. Although the incidence and
nature of the events were similar to those described pre-
viously from the olanzapine LAI clinical trials [19, 22],
too few events occurred to obtain a detailed meaningful
analysis at this time. Furthermore, the average duration
of olanzapine LAI exposure for all patients was
0.768 years in this interim analysis. Final study results
will provide a better estimate of exposure.
Certain limitations to this study must be noted. First,
because an observational study design was used, patients
were not randomized to treatment and the results may
have been affected by selection bias. Although the
strength of an observational design is its ability to dir-
ectly observe individuals in their natural setting and to
better reflect clinical practice, the resulting populations
of patients (and investigators) who elect to participate in
the study may be determined by individual preferences,
practice patterns, or policy decisions [31]. It also should
be noted that data collected at baseline regarding previ-
ous hospitalizations and medications represent retro-
spective data and are subject to limitations in recall or
reporting. In addition, the recall period for reporting al-
cohol and recreational drug use was limited to the 24 h
prior to receiving the first injection of olanzapine LAI
and may not fully characterize the history and extent of
consumption by study participants. Caution should be
used when interpreting the association between acute
use of these predictor variables and psychiatric hospitali-
zations. Adequate numbers were not available to analyze
12-month post study enrollment hospitalization data, so
these data were not included in this report. Furthermore,
the types and amount of data collected in an observa-
tional study are more limited than would be the case in
a controlled clinical trial; data collection was kept to a
minimum to not burden investigators and patients and
to not interfere with typical clinical practice.
Conclusions
The 6-month results indicate a significant reduction in
the incidence and days of hospitalization from the
period before to the period after olanzapine LAI initi-
ation. The current results support findings in the
published literature that depot antipsychotics reduce
relapse and hospitalization. Psychiatric hospitalization
in the previous 12 months and recreational drug use in the
24 h prior to baseline study visit were identified as poten-
tial predictors of time to first psychiatric hospitalization.
Because findings were from an interim analysis, final study
results will be necessary to determine whether the
current findings are maintained and to elaborate fur-
ther on clinical presentation, outcomes, and potential
risk factors associated with PDSS.
Table 4 Risk factors for time to first psychiatric hospitalizationa
95 % Confidence
Interval
Variable Hazard Ratio Lower Upper P-valueb
Psychiatric hospitalization
in prior 12 months
5.00 2.41 10.37 <0.0001
Recreational drug use within
24 h of baseline study visit
5.90 1.41 24.59 0.015
aAnalysis included only patients who started treatment with olanzapine LAI at
time of study entry
bCox regression model was applied
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Availability of supporting data
Additional information about the dataset and analyses
are available upon request, but the data files are the
proprietary property of Eli Lilly and Company.
Additional files
Additional file 1: A STROBE checklist for observational studies.
(PDF 22 kb)
Additional file 2: A list of participating centers and names of ethics
boards. (XLS 144 kb)
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